CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

Reyes, Ryan M.; Zhang, Chenghao; Deng, Yilun; Ji, Niannian; Mukherjee, Neelam; Padrón, Álvaro; Clark, C. Brendan; Svatek, Robert S.; Curiel, Tyler J.

doi:10.1080/2162402x.2021.2006529

OncoImmunology

2021

DOI: 10.1080/2162402x.2021.2006529

|View full text |Cite

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

Ryan M. Reyes

Chenghao Zhang

Yilun Deng

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review

Tang,

Xu,

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Bladder cancer is one of the most frequent malignant tumors of the urinary system. The prevalence of bladder cancer among men and women is roughly 5:2, and both its incidence and death have been rising steadily over the past few years. At the moment, metastasis and recurrence of advanced bladder cancer—which are believed to be connected to the malfunction of multigene and multilevel cell signaling network—remain the leading causes of bladder cancer-related death. The therapeutic treatment of bladder cancer will be greatly aided by the elucidation of these mechanisms. New concepts for the treatment of bladder cancer have been made possible by the advancement of research technologies and a number of new treatment options, including immunotherapy and targeted therapy. In this paper, we will extensively review the development of the tumor microenvironment and the possible molecular mechanisms of bladder cancer.

show abstract

Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review

Tang,

Xu,

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies

Noel,

Hassouneh,

Svatek

et al. 2023

Cancer Immunology Research

View full text Add to dashboard Cite

Bladder tumors have a high mutational burden and tend to be responsive to immune therapies; however, response rates remain modest. To date, immunotherapy in bladder cancer has largely focused on enhancing T-cell immune responses in the bladder tumor microenvironment. It is anticipated that other immune cells, including innate lymphoid cells (ILC), which play an important role in bladder oncogenesis and tumor suppression, could be targeted to improve response to existing therapies. ILCs are classified into five groups: natural killer cells, ILC1s, ILC2s, ILC3s, and lymphoid tissue inducer cells. ILCs are pleiotropic and play dual and sometimes paradoxical roles in cancer development and progression. Here, a comprehensive discussion of the current knowledge and recent advancements in understanding the role of ILCs in bladder cancer is provided. We discuss the multifaceted roles that ILCs play in bladder immune surveillance, tumor protection, and immunopathology of bladder cancer. This review provides a rationale for targeting ILCs in bladder cancer, which is relevant for other solid tumors.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

Cited by 2 publications

References 52 publications

Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review

Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review

Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies

Contact Info

Product

Resources

About